Crinetics Pharmaceuticals, Inc.: Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY (paltusotine) Provides Durable, Consistent Acromegaly Control

Source Summary

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable o...